Treatment Considerations and Sequencing in Multiple Myeloma
The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.
Read More
CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape
A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.
Read More
GPRC5D-Targeting Bispecifics in Multiple Myeloma
The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.
Read More
Adverse Effects Related to Bispecifics in Multiple Myeloma
Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.
Read More
Step-Up Dosing Practices for Bispecifics in Multiple Myeloma
Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.
Read More
Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma
Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.
Read More
Potential Role for CAR T-Cell Therapy in MM at Early Relapse
Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.
Read More
Treatment of Multiple Myeloma at Early Relapse
A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.
Read More
The Evolving Treatment Paradigm for Transplant Ineligible MM
The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.
Read More
Role of Transplant and MRD in Newly Diagnosed MM
Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.
Read More
Advances in the Treatment of High-Risk MM
Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.
Read More
Highlights from ASH 2023 in Transplant-Eligible NDMM
Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.
Read More
Unmet Needs and Future Perspectives in Multiple Myeloma Care
The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.
Read More
Does Belantamab Have a Place in Multiple Myeloma Treatment?
The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.
Read More
Preventing Infection in Patients with Multiple Myeloma During Treatment
Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.
Read More
Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.
Read More
Targets in Multiple Myeloma: FcRH5
Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.
Read More
Targets in Multiple Myeloma: GPRC5D
Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.
Read More
Data Updates on Immunotherapy Combinations in Multiple Myeloma
Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.
Read More
Retreatment with a BCMA-Targeting Bispecific for R/R MM
Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.
Read More
BCMA-Targeting Bispecifics in Relapsed/Refractory Multiple Myeloma
Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.
Read More
CD38 Monoclonal Antibodies for Early Relapsed Multiple Myeloma and the Risk of COVID Infection
The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.
Read More
Considerations for Treatment Decision-Making in Early-Relapse Multiple Myeloma
Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.
Read More